AHEAD INTERNATIONAL AND GERMAN STUDIES: 6-YEAR INTERIM EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH HEMOPHILIA A RECEIVING ANTIHEMOPHILIC FACTOR (RECOMBINANT) IN A REAL-WORLD SETTING

J. Oldenburg (1) , M. C. Ozelo (2) , R. Klamroth (3) , B. Guillet (4) , A. Huth-Kuehne (5) , K. Kurnik (6) , K. Khair (7) , D. A. Tsakiris (8) , J. Botha (9) , A. Fernandez (9) , S. Regensburger (9) , L. Tang (9) , E. Santagostino (10)

1 UKB - Universitätsklinikum Bonn
2 UNICAMP - Universidade Estadual de Campinas = University of Campinas
3 Vivantes Klinikum Friedrichshain
4 Irset - Institut de recherche en santé, environnement et travail
5 SRH Kurpfalzhospital
6 Klinikum der Universität [München]
7 GOSH - Great Ormond Street Hospital for Children [London]
8 University Hospital Basel [Basel]
9 Shire [Zug]
10 Fondazione Luigi Villa - Angelo Bianchi Bonomi Hemophilia and Thrombosis Center [Milan, Italy]

Domains: Life Sciences [q-bio]

J. Oldenburg, M. C. Ozelo, R. Klamroth, B. Guillet, A. Huth-Kuehne, et al.. AHEAD INTERNATIONAL AND GERMAN STUDIES: 6-YEAR INTERIM EFFECTIVENESS AND SAFETY OUTCOMES IN PATIENTS WITH HEMOPHILIA A RECEIVING ANTIHEMOPHILIC FACTOR (RECOMBINANT) IN A REAL-WORLD SETTING. Haemophilia, 2020, 26 (S2), pp.87-87. ⟨10.1111/hae.13911⟩. ⟨hal-02501205⟩